Approved — for a specific indication. Tesamorelin is FDA-approved (Egrifta) to reduce excess visceral fat in HIV-associated lipodystrophy — a narrow, prescription indication. Use for other goals is off-label / not established. Educational only, not medical advice.
What it is
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH). Like CJC-1295 it works on the GHRH pathway — but unlike those RUO peptides, tesamorelin completed the trials to earn an FDA approval.
Mechanism
It binds the GHRH receptor on the pituitary, stimulating physiological growth-hormone release and raising IGF-1. In its approved indication this reduces visceral adipose tissue.1
Evidence & status
Approved: FDA-approved (Egrifta) for HIV-associated lipodystrophy, backed by Phase 3 trials.2
Other uses: not established; a good example of "approved for X does not mean proven for Y."
WADA: GH secretagogues are prohibited (S2) for tested athletes.
For educational and research purposes only. This content is not medical advice. Tesamorelin is a prescription drug; obtain and use medicines only under a licensed professional. Free Peptide University does not sell compounds.